TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00818883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil and chlorthalidone
Description: Azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablet, orally, once daily and hydrochlorothiazide placebo-matching tablets, orally, once daily for up to 10 weeks.~For participants who do not achieve target blood pressure by Week 6, the dose of chlorthalidone will be increased for the remaining 4 weeks of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil and hydrochlorothiazide
Description: Azilsartan medoxomil 40 mg, tablets, orally, once daily and hydrochlorothiazide 12.5 mg, tablets, orally, once daily for up to 10 weeks.~For participants who do not achieve target blood pressure by Week 6, the dose of hydrochlorothiazide will be increased for the remaining 4 weeks of treatment.
Study: NCT02005536

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMOVAX POLIO®: Inactive Poliovirus Vaccine
Description: 0.5 mL, Subcutaneous
Study: NCT04583852

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AIVÍA, Ultra-Brightening Spot Micro-needle Patch
Description: a dissolving micro-needle patch, contains active ingredients

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Micro-needle Patch
Description: matching placebo will be provided as a dissolving micro-needle patch
Study: NCT01893905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS+SG
Description: Chondroitin sulfate+glucosamine sulfate orally administered once a day for 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of chondroitin sulfate+glucosamine sulfate orally administered once a day for 24 weeks.
Study: NCT02425579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Carbon Monoxide at 100ppm (4 participants)
Description: Inhaled Carbon Monoxide at 100ppm for up to 90 minutes daily for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Inhaled Carbon Monoxide at 100ppm (2 participants)
Description: Inhaled Medical Air for up to 90 minutes daily for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Carbon Monoxide at 200ppm (4 participants)
Description: Inhaled Carbon Monoxide at 200ppm for 90 minutes daily for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Inhaled Carbon Monoxide at 200ppm (2 participants)
Description: Inhaled Medical Air for up to 90 minutes daily for 5 days
Study: NCT02441972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Al-NOTA-PRGD2 PET/CT
Description: 18F-Al-NOTA-PRGD2(PET imaging agent) given by vein before PET scans.Perform PET/CT for each enrolled volunteer or patient at 60-90min.
Study: NCT02230007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEOPA
Description: 3 sessions of reeducation using MEOPA
Study: NCT04478019

Intervention type: DRUG
Group type: OTHER
Intervention: 10% Povidone-iodine nasal decolonization swab plus 0.12% CHG oral rinse
Description: 2 swab sticks of 10% povidone-iodine in each nares and 0.12% CHG oral rinse

Intervention type: DRUG
Group type: OTHER
Intervention: 10% Povidone-iodine nasal decolonization swab plus 0.12% CHG oral rinse
Description: 2 swab sticks of 10% povidone-iodine in each nares and 0.12% CHG oral rinse
Study: NCT02310165

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Z-tract Insertion Technique

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Coaxial Insertion Technique
Study: NCT00686959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: infusion over 10 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: infusion over 60 minutes with adequate anti-emetic treatment and appropriate hydration per local practice guidelines

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: infusion over 60 minutes with adequate anti-emetic treatment and appropriate hydration per local practice guidelines

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: administered per local practice guidelines over a minimum of 30 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: administered over 6-10 minutes infusion per local practice guidelines

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: administered as a 3-hour infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: administered per local practice guidelines over 30 minutes

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic Radiation Therapy (TRT)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Radiation Therapy (TRT)
Study: NCT04058223

Intervention type: DEVICE
Intervention: Hemorrhoidopexy
Description: stapled hemorrhoidopexy
Study: NCT02429271

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Coronary Intervention (PCI)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Coronary Intervention (PCI)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary Angiography

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary Angiography
Study: NCT00868400

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: commercially available high-carbohydrate beverage
Description: 800 ml before the day of surgery, and additional 400 ml two hours prior to surgery

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: flavored water
Description: will be given in doses equal to those of high-carbohydrate beverage
Study: NCT02802436

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Extraction with socket graft
Description: Extraction will be done as usual standard of care to preserve socket walls. Sockets will be measured at all 4 line angles for depth with the same periodontal probe, Buccal-Lingual dimension will be measured prior to graft placement. Graft material (mineralized cortical/cancellous Bone Powder 250-1000µ) will be used for both sites. Volume of graft used will be recorded. Both sites will be filled slightly below marginal bone level (1mm). Test site will be injected with Bioactive Agent. At 3 levels apical 1/3rd, middle 1/3rd and coronal 1/3rd. Control site will be injected with saline (or vehicle) at same levels. Occlusal orifice will be closed with Collagen plug adjusted for depth to meet free gingival margins and then sutured with 4-0 PGA (Vicryl)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extraction with socket graft
Description: Extraction will be done as usual standard of care to preserve socket walls. Sockets will be measured at all 4 line angles for depth with the same periodontal probe, Buccal-Lingual dimension will be measured prior to graft placement. Graft material (mineralized cortical/cancellous Bone Powder 250-1000µ) will be used for both sites. Volume of graft used will be recorded. Both sites will be filled slightly below marginal bone level (1mm). Test site will be injected with Bioactive Agent. At 3 levels apical 1/3rd, middle 1/3rd and coronal 1/3rd. Control site will be injected with saline (or vehicle) at same levels. Occlusal orifice will be closed with Collagen plug adjusted for depth to meet free gingival margins and then sutured with 4-0 PGA (Vicryl)
Study: NCT04107974

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gastropexy.
Description: Two T-fasteners for G-tube insertion (gastropexy).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-Gastropexy
Description: Insertion of G-tube in absence of T-fasteners.
Study: NCT00812734

Intervention type: PROCEDURE
Intervention: Blood sampling for genomics; harvesting of a sample of intercostal muscle for proteomics (thoracotomies only)
Description: Blood sampling for genomics; harvesting of a sample of intercostal muscle for proteomics (thoracotomies only)
Study: NCT03943056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB091
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB091
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB091
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB091
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB091
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB091
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB091
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB091
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as specified in the treatment arm.
Study: NCT02507427

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIM-Eclipse
Description: Using NIM-Eclipse, nerve monitoring and mapping are performed
Study: NCT02962570

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: On Demand Oxygen Delivery
Description: Supplemental oxygen flow is controlled such that it is on only during inhalation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Traditional, Always-On, Oxygen Delivery
Description: Supplemental oxygen flow is constantly on, irrespective of whether the patient is inhaling or exhaling.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxygen Flow Stopped
Description: Supplemental oxygen flow is stopped completely for a brief period to allow undisturbed end-tidal oxygen and CO2 measurements
Study: NCT02841826

Intervention type: OTHER
Group type: OTHER
Intervention: IUD

Intervention type: OTHER
Group type: OTHER
Intervention: IUD

Intervention type: OTHER
Group type: OTHER
Intervention: Uterine sounding

Intervention type: RADIATION
Group type: OTHER
Intervention: Transvaginal ultrasound
Study: NCT00626548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD4054
Description: 10 mg once daily oral dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Palcebo
Description: Matching Plcebo oral tablet once daily
Study: NCT01449266

Intervention type: DRUG
Group type: OTHER
Intervention: Dotarem® IV injection at 0.1 mmol/kg
Description: Dotarem® was IV administered at a dose of 0.1 mmoL/kg (0.2 mL/kg).
Study: NCT00906425

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Straumann Bone Level Implant
Description: Straumann Bone Level Implant, SLActive surface, diameter 4.1, length 8, 10, 12, and 14 mm

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Straumann Bone Level Implant
Description: Straumann Bone Level Implant, SLActive surface, diameter 4.1, length 8, 10, 12, and 14 mm
Study: NCT05761626

Intervention type: OTHER
Intervention: MP < 17 J/min
Description: assessment of the ventilatory variables according to the MP value (\< or \>= 17 J/min)
Study: NCT05742529

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TIP
Description: TIP An 8F straight sound is passed into the hypospadiac meatus to assess skin coverage over the urethra., a circumscribing incision is made 2 mm proximal to the meatus, a U-shaped incision is extended proximally to healthy skin The key step in the operation is a midline relaxing incision made from within the meatus to the distal extent of the plate. This incision extends through the epithelial surface of the plate deeply into underlying connective tissues down to the corpora cavernosaNext, a 6F stent is passed into the bladder for postoperative urinary diversion. Then the urethral plate is tubularized. , stitches are ever taken further distally to ensure the neomeatus has a generous oval openingticular closures. .

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: STITCH BY STITCH
Description: SBS in brief Operative technique :starts with penile degloving, preparation of the flap (Site of hypospadic meatus is determined after degloving). Creation of a narrow strip of the urethral plate with wide glanular wings is done using bilateral incisions which are extended to the tip of the glans. The width of the urethral plate is about 3 mm then we suture the flap to the narrow urethral plate in two layers in continuous manner using vicryl 6/0 over a suitable plastic catheter. Triangular (Vshape) area of the distal part of the flap is excised a the midline. After this we anastomose the flap to thetip of the glans. The glans appears opened in the midline as inverted V shape. Closure of the glans is finished in the midline using three mattress interrupted sutures with another three simple stitches are used in between
Study: NCT04034576

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy of trainee therapists
Description: In all three treatment arms, trainee therapists perform a cognitive behavior therapy (CBT) under conditions of the German health care system. This treatment is not a manualized intervention, but rather based on individualized treatment plans that have been developed together with expert supervisors during a five session diagnostic stage. Treatment duration is 24 sessions, while on average every fourth is supervized by an CBT expert therapist.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavior therapy of trainee therapists
Description: In all three treatment arms, trainee therapists perform a cognitive behavior therapy (CBT) under conditions of the German health care system. This treatment is not a manualized intervention, but rather based on individualized treatment plans that have been developed together with expert supervisors during a five session diagnostic stage. Treatment duration is 24 sessions, while on average every fourth is supervized by an CBT expert therapist.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive behavior therapy of trainee therapists
Description: In all three treatment arms, trainee therapists perform a cognitive behavior therapy (CBT) under conditions of the German health care system. This treatment is not a manualized intervention, but rather based on individualized treatment plans that have been developed together with expert supervisors during a five session diagnostic stage. Treatment duration is 24 sessions, while on average every fourth is supervized by an CBT expert therapist.
Study: NCT01393678

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NISSEL
Description: Biphenyl Dimethyl Dicarboxylate 25mg ............. 1 cap

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PENNEL
Description: Biphenyl Dimethyl Dicarboxylate 25mg \& garlic oil 50mg ............. 1cap
Study: NCT01806688

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gluten-free high protein snack #1
Description: buckwheat groats 30g serving

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gluten-free snack with similar energy density but 1/2 the protein as snack #1
Description: 32g serving of corn nuts

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non-caloric control
Description: water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non-caloric control
Description: water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gluten-free high protein and high fibre snack #2
Description: buckwheat and pinto bean flour pita bread 50g serving

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gluten-free snack with similar energy density, but less protein and fibre than snack #2
Description: 50g serving of rice bread
Study: NCT01991470

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enlite sensors
Description: Subject wears enlite sensor first and followed by enlite 3 sensor.
Study: NCT02216071

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprodex®
Description: Treatment of acute otitis externa (AOE) when administered twice daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXL CDOS (Ciprofloxacin 0.3% and Dexamethasone 0.1%) Sterile Otic Suspension
Description: Treatment of acute otitis externa (AOE) when administered twice daily for 7 days
Study: NCT00821834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel (SR25990)
Description: Form: tablets~Route: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ticlopidine
Description: Form: tablets~Route: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Form: tablets~Route: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Form: tablets~Route: oral
Study: NCT03443765

Intervention type: DIAGNOSTIC_TEST
Intervention: Detection of Plasma levels of 25(OH) vitamin D by ELISA technique
Description: Five milliliters of peripheral venous blood sample will be taken (after 8-12 hours of fasting) from each participant and will be collected into HumaTube Serum Gel - C/A for ELISA. Serum will be appropriately obtained and stored at -20°C maximum of 30 days. Plasma levels of 25(OH) vitamin D will be detected by enzyme-linked immunosorbent assay (ELISA) technique.

Intervention type: DIAGNOSTIC_TEST
Intervention: Detection of Plasma levels of 25(OH) vitamin D by ELISA technique
Description: Five milliliters of peripheral venous blood sample will be taken (after 8-12 hours of fasting) from each participant and will be collected into HumaTube Serum Gel - C/A for ELISA. Serum will be appropriately obtained and stored at -20°C maximum of 30 days. Plasma levels of 25(OH) vitamin D will be detected by enzyme-linked immunosorbent assay (ELISA) technique.

Intervention type: DIAGNOSTIC_TEST
Intervention: Detection of Total serum immunoglobulin E by ELISA technique
Description: Five milliliters of peripheral venous blood sample will be taken (after 8-12 hours of fasting) from each participant and will be collected into HumaTube Serum Gel - C/A for ELISA. Serum will be appropriately obtained and stored at -20°C maximum of 30 days. Total serum immunoglobulin E will be detected by enzyme-linked immunosorbent assay (ELISA) technique.

Intervention type: DIAGNOSTIC_TEST
Intervention: Detection of Total serum immunoglobulin E by ELISA technique
Description: Five milliliters of peripheral venous blood sample will be taken (after 8-12 hours of fasting) from each participant and will be collected into HumaTube Serum Gel - C/A for ELISA. Serum will be appropriately obtained and stored at -20°C maximum of 30 days. Total serum immunoglobulin E will be detected by enzyme-linked immunosorbent assay (ELISA) technique.
Study: NCT02730078

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VEMOFIT
Description: The VEMOFIT intervention involves four biweekly two hours sessions over a period of about six weeks, and a booster at three months follow-up. It consists of a mixture of 1) exploring illness perceptions and personal meanings of diabetes, 2) cognition-focused education on diabetes and practical skills in self-management and 3) emotion-focused training on recognising emotions in the self and others. Each group will consist of 10 to 12 participants of equal representation by the patients and their significant others.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention-meetings (AG)
Description: Patients in the health clinics randomised to the AG, will receive the usual T2D care by the clinic doctors and education by the clinic paramedics based on the recommendations in the Malaysian clinical guidelines. At T1, T2 and T4, patients (not including their significant others) in AG will be gathered in groups of 10-12 people for the primary and secondary outcomes evaluation. This session will include general discussion on feeling about and coping with T2D, social support at home and satisfaction with treatment and care received at the respective clinics.
Study: NCT03267745

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amino Acid
Description: 23.7 g amino acid 3 times daily for 28 days

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breg Brace single-leg immobilization
Description: 7 days of single leg immobilization; randomized to leg; knee brace will be worn in a fixed flexion position at 140°.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Breg Brace single-leg immobilization
Description: 7 days of single leg immobilization; randomized to leg; knee brace will be worn in a fixed flexion position at 140°.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Excipient-matched placebo 3 times daily for 28 days
Study: NCT01050647

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 17-Hydroxyprogesterone Caproate
Description: Weekly injections of 17-hydroxyprogesterone caproate.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Caster Oil injections
Description: Weekly injection of Caster Oil (Placebo) until patient reached 34 weeks gestation.